{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:31Z","timestamp":1792239091288,"version":"4.4.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>\n                    mRNA vaccines, as a novel vaccine platform, have rapidly become a global research hotspot driven by the COVID-19 pandemic. This study employs a systematic analysis method based on clinical trial registries to conduct a descriptive statistical analysis of mRNA vaccine-related trials registered in the\n                    <jats:uri>ClinicalTrials.gov<\/jats:uri>\n                    database from March 2000 to July 2025. We compared characteristics such as the number of trials, geographical distribution, study type, funding sources, trial design, and indications, and used chi-square tests and Fisher\u2019s exact tests for inter-group difference analysis. The results show that the number of mRNA vaccine clinical trials has experienced explosive growth after the pandemic, presenting obvious pandemic-driven characteristics and geographical differences. There are significant differences in registration characteristics and trial design among China, the United States, and Europe (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt;0.01). Indications have rapidly expanded from infectious diseases to multiple fields such as tumors, autoimmune diseases, and metabolic diseases, indicating that mRNA technology is transforming from an infectious disease prevention tool into a platform technology with broad therapeutic potential. From the perspective of clinical trial registration, this study provides empirical evidence for understanding the global research status, regional strategy differences, and future development directions of mRNA vaccines. It offers insights for vaccine development planning, international regulatory coordination, and global clinical trial strategic planning, assisting researchers, enterprises, and policymakers in making optimal decisions.\n                  <\/jats:p>","DOI":"10.3389\/fpubh.2026.1738942","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:55:12Z","timestamp":1769064912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data"],"prefix":"10.3389","volume":"14","author":[{"given":"Sijia","family":"Liu","sequence":"first","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwan","family":"Xiang","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancai","family":"Wu","sequence":"additional","affiliation":[{"name":"Institution for Drug Clinical Trials, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1326154","DOI":"10.3389\/fpubh.2023.1326154","article-title":"Two centuries of vaccination: historical and conceptual approach and future perspectives","volume":"11","author":"Montero","year":"2024","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1080\/21645515.2016.1158369","article-title":"Historical context and the roots of Jenner's discovery","volume":"12","author":"Rusnock","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"ref3","first-page":"83","article-title":"The application of molecular biology to the development of novel vaccines","volume":"251","author":"Kniskern","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"1989","journal-title":"Semin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1016\/j.vaccine.2021.07.033","article-title":"Pneumococcal conjugate vaccine dose-ranging studies in humans: a systematic review","volume":"39","author":"Lucinde","year":"2021","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref8","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"103458","DOI":"10.1016\/j.drudis.2022.103458","article-title":"Current state of, prospects for, and obstacles to mRNA vaccine development","volume":"28","author":"Aljabali","year":"2023","journal-title":"Drug Discov Today"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3390\/vaccines10050709","article-title":"Universal flu mRNA vaccine: promises, prospects, and problems","volume":"10","author":"Deviatkin","year":"2022","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.ircmb.2022.04.011","article-title":"Advances in mRNA vaccines","volume":"372","author":"Li","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/j.lanwpc.2021.100097","article-title":"The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): a systematic review","volume":"8","author":"Chen","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ymthe.2019.03.009","article-title":"In vitro-transcribed mRNA therapeutics: out of the shadows and into the spotlight","volume":"27","author":"Karik\u00f3","year":"2019","journal-title":"Mol Therapy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.4049\/jimmunol.146.5.1522","article-title":"Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor\/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro","volume":"146","author":"Dett","year":"1991","journal-title":"J Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"11421","DOI":"10.1016\/S0021-9258(18)60481-8","article-title":"Regulation of expression of the gene encoding the major surfactant protein (SP-A) in human fetal lung in vitro. Disparate effects of glucocorticoids on transcription and on mRNA stability","volume":"264","author":"Boggaram","year":"1989","journal-title":"J Biol Chem"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2342592","DOI":"10.1080\/21645515.2024.2342592","article-title":"Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size","volume":"20","author":"Shi","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/biom15030359","article-title":"Revolutionizing mRNA vaccines through innovative formulation and delivery strategies","volume":"15","author":"Fatima","year":"2025","journal-title":"Biomolecules"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2597629","DOI":"10.1080\/21645515.2025.2597629","article-title":"mRNA vaccine platforms and novel delivery systems: from mechanistic principles to clinical translation","volume":"21","author":"Yang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/ame2.70018","article-title":"Respiratory virus mRNA vaccines: mRNA design, clinical studies, and future challenges","volume":"8","author":"Zheng","year":"2025","journal-title":"Anim Models Exp Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref22","first-page":"9","article-title":"FDA authorizes Moderna COVID-19 vaccine","volume":"63","year":"2021","journal-title":"Med Lett Drugs Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2002083","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/vaccines9070734","article-title":"Detailed dissection and critical evaluation of the Pfizer\/BioNTech and Moderna mRNA vaccines","volume":"9","author":"Xia","year":"2021","journal-title":"Vaccine"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/164_2024_723","article-title":"Reaching outer space and enabling the mRNA revolution: a critical role of partnerships for successful drug and vaccine development","volume":"286","author":"Seshire","year":"2024","journal-title":"Handb Exp Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/jmahp12040025","article-title":"Developer and partnership differences in COVID-19 and other infections: insights from DNA vaccines","volume":"12","author":"Okuyama","year":"2024","journal-title":"J Market Access Health Policy"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.jiph.2024.102538","article-title":"Preparing the developing world for the next pandemic: evidence from China's R&D blueprint for emerging infectious diseases","volume":"17","author":"Ma","year":"2024","journal-title":"J Infect Public Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3201\/eid3101.230638","article-title":"Research and development of medical countermeasures for emerging infectious diseases, China 1990-2022","volume":"31","author":"Ma","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/eurpub\/ckac103","article-title":"An overview of personalized medicine landscape and policies in the European Union","volume":"32","author":"Beccia","year":"2022","journal-title":"Eur J Pub Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"ref31","first-page":"145","volume-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science","author":"Krienke","year":"2021"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jconrel.2024.09.020","article-title":"LNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice","volume":"375","author":"Chen","year":"2024","journal-title":"J Control Release"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref34","first-page":"899","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes science","author":"Arevalo","year":"2022"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against respiratory syncytial virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e1857","DOI":"10.1002\/wnan.1857","article-title":"Nanovaccines to combat virus-related diseases","volume":"15","author":"Wu","year":"2023","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"127530","DOI":"10.1016\/j.vaccine.2025.127530","article-title":"A mRNA vaccine encoding for a 60-mer Nipah virus G glycoprotein nanoparticle elicits a robust neutralizing antibodies response against the Nipah virus","volume":"62","author":"Brandys","year":"2025","journal-title":"Vaccine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/vaccines9121464","article-title":"mRNA vaccine protects against Zika virus","volume":"9","author":"Medina-Mag\u00fces","year":"2021","journal-title":"Vaccine"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"122331","DOI":"10.1016\/j.lfs.2023.122331","article-title":"Vaccine development: current trends and technologies","volume":"336","author":"Poria","year":"2024","journal-title":"Life Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases - advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-021-01465-w","article-title":"Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Mol Cancer"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/vaccines12010009","article-title":"Anti-idiotypic mRNA vaccine to treat autoimmune disorders","volume":"12","author":"Niazi","year":"2023","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1080\/17435889.2025.2530242","article-title":"Research progress on mRNA drug delivery strategies in the nervous system","volume":"20","author":"Yang","year":"2025","journal-title":"Nanomedicine (Lond)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14797\/mdcvj.1169","article-title":"Future impact of mRNA therapy on cardiovascular diseases","volume":"18","author":"Cooke","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv Mater"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13037-021-00291-9","article-title":"Review the safety of COVID-19 mRNA vaccines: a review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf Surg"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1336906","DOI":"10.3389\/fimmu.2024.1336906","article-title":"The mRNA-LNP vaccines - the good, the bad and the ugly?","volume":"15","author":"Igy\u00e1rt\u00f3","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1738942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:55:14Z","timestamp":1769064914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1738942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":50,"alternative-id":["10.3389\/fpubh.2026.1738942"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1738942","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1738942"}}